<table>
<thead>
<tr>
<th><strong>Title</strong></th>
<th>Different cell kinetic changes in rat stomach cancer after treatment with celecoxib or indomethacin: Implications on chemoprevention</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Author(s)</strong></td>
<td>Yu, J; Tang, BD; Leung, WK; To, KF; Bai, AHC; Zeng, ZR; Ma, PK; Go, MYY; Hu, PJ; Sung, JJY</td>
</tr>
<tr>
<td><strong>Citation</strong></td>
<td>World Journal Of Gastroenterology, 2005, v. 11 n. 1, p. 41-45</td>
</tr>
<tr>
<td><strong>Issued Date</strong></td>
<td>2005</td>
</tr>
<tr>
<td><strong>URL</strong></td>
<td><a href="http://hdl.handle.net/10722/162849">http://hdl.handle.net/10722/162849</a></td>
</tr>
<tr>
<td><strong>Rights</strong></td>
<td>This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.</td>
</tr>
</tbody>
</table>
Different cell kinetic changes in rat stomach cancer after treatment with celecoxib or indomethacin: Implications on chemoprevention

Jun Yu, Bao-Dong Tang, Wai K. Leung, Ka-Fai To, Alfa H.C. Bai, Zhi-Rong Zeng, Po-Ki Ma, Minnie Y.Y. Go, Pin-Jin Hu, Joseph J.Y. Sung

AIM: Mechanisms underlying the chemopreventive effects of cyclooxygenase (COX) inhibitors remain elusive. We have previously shown that celecoxib but not indomethacin could prevent carcinogen-induced gastric cancer development in Wistar rats. This chemopreventive effect appeared to be independent of COX-2 and prostaglandin (PG) E₂ suppression since the lowest PGE₂ was obtained in indomethacin group. This study compared the cell kinetic changes in stomachs of rats after treatment with celecoxib (5, 10, 20 mg/(kg·d)) or indomethacin (3 mg/(kg·d)) to gain more insights into the chemopreventive mechanism.

METHODS: The apoptosis and proliferation indexes in gastric tumor, adjacent non-cancer tissues and normal gastric tissues were determined. Apoptosis was quantified by apoptotic nuclei counting and TUNEL, whereas proliferation was determined by Ki67 immunostaining.

RESULTS: Treatment with either celecoxib or indomethacin inhibited gastric tumor proliferation by more than 65% (P<0.02). However, celecoxib caused a dose-dependent increase in apoptosis (P<0.05) which was not seen in indomethacin-treated tumors (P = 0.54). The highest apoptosis to proliferation ratio was seen in tumors treated with celecoxib at 10 mg/(kg·d). Treatment with this dose of celecoxib was associated with the lowest incidence of gastric cancer development.

CONCLUSION: Our findings suggest that the difference in chemopreventive effects of indomethacin and celecoxib in this animal model of gastric carcinogenesis is largely due to the differential cell kinetic changes, which does not correlate with the degree of COX-2 and PG suppression.

© 2005 The WJG Press and Elsevier Inc. All rights reserved.

Key words: Stomach cancer; Celecoxib; Indomethacin; Cell kinetics
Briefly, 4 week-old grade 2 male Wistar rats (weighing around 60 g) were used. The rats were fed with food and water ad libitum and maintained on hardwood bedding under a 12-h light/dark cycle. Animals were weighed weekly during the experiment.

Primary gastric adenocarcinomas were induced by oral administration of N-methyl-N'-nitro-N-nitrosoguanidine (MNNNG) as described previously[17,18]. MNNNG (Fluko, Germany) was prepared every other day with distilled water into a concentration of 100 µg/mL and was given to rats as drinking water. In addition, 1 mL of 10% sodium chloride was given weekly by oral gavage in the initial 6 wk to enhance gastric cancer development[19]. All experiments were approved by the Sun Yat-Sen University Animal Experimentation and Ethics Committee.

Rats were randomly allocated to 6 different treatment groups as shown in Table 1: Group A: untreated control (n = 5), group B: MNNNG control (n = 16), group C: MNNNG plus celecoxib at 5 mg/(kg·d) (n = 17), group D: MNNNG plus celecoxib at 10 mg/(kg·d) (n = 16), group E: MNNNG plus celecoxib at 20 mg/(kg·d) (n = 16) and group F: MNNNG plus indomethacin at 3 mg/(kg·d) (n = 16). The dosages of these drugs were based on corresponding human doses and previous animal chemopreventive studies[10,11]. All drug treatments were commenced on d 7 after the introduction of MNNNG and continued for 40 wk. All animals were then sacrificed at the end of study.

Gastric tumor (T), adjacent non-tumor site (NT), macroscopically normal gastric mucosa from non-tumor rats (N) in the same treatment group were obtained. In untreated control rats, normal gastric tissues were obtained as control (C). All gastric tissues were fixed in 10% buffered formalin for histological processing.

**Table 1** Incidence of gastric tumors in different treatment groups

<table>
<thead>
<tr>
<th>Group Treatment</th>
<th>Total no. of rats</th>
<th>Total no. of rats with tumor</th>
<th>Tumor incidence (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A Control</td>
<td>5</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>B MNNNG alone</td>
<td>16</td>
<td>12</td>
<td>75.0</td>
</tr>
<tr>
<td>C MNNNG+celecoxib 5 mg/kg</td>
<td>17</td>
<td>12</td>
<td>70.6</td>
</tr>
<tr>
<td>D MNNNG+celecoxib 10 mg/kg</td>
<td>16</td>
<td>3</td>
<td>18.8</td>
</tr>
<tr>
<td>E MNNNG+celecoxib 20 mg/kg</td>
<td>16</td>
<td>5</td>
<td>31.3</td>
</tr>
<tr>
<td>F MNNNG+indomethacin 3 mg/kg</td>
<td>16</td>
<td>11</td>
<td>68.8</td>
</tr>
</tbody>
</table>

RESULTS

**Chemopreventive effects of celecoxib**

The percentage of rats that developed gastric cancer in each treatment group is summarized in Table 1. Whilst none of the control rats in group A developed gastric cancer, 75% of MNNNG treated rats (group B) had gastric cancer (P = 0.002, Table 1). Treatment with celecoxib at 10 mg/(kg·d) (18.8%, P = 0.004) and 20 mg/(kg·d) (31.3%, P = 0.052) was associated with lower incidences of gastric cancer development than MNNNG control. However, administration of celecoxib 5 mg/kg or indomethacin 3 mg/kg had no significant reduction in tumor incidence.

**Effect of celecoxib or indomethacin on gastric epithelial cell apoptosis**

The mean apoptotic indexes in gastric tumors, their corresponding adjacent normal tissues and non-tumor gastric tissues of different treatment groups are shown in Figure 2A. The apoptotic index was generally higher in gastric tumors than in their adjacent non-tumor and normal gastric tissues (P < 0.005, ANOVA). Specifically, there was a significant difference in the apoptotic indexes among tumor, adjacent non-cancer tissues and normal gastric tissues in group B as MNNNG control (P = 0.001), groups C to E treated with celecoxib (P < 0.005) and group F treated with indomethacin (P = 0.003).

Whilst the mean apoptotic index was 0.50% in MNNNG treated tumors, there appeared to be a dose-dependent increase in the apoptotic index of gastric tumors treated with celecoxib (P < 0.05, ANOVA). The corresponding mean apoptotic indexes in rats treated with celecoxib 5 mg/(kg·d), celecoxib 10 mg/(kg·d) and celecoxib 20 mg/(kg·d) were 0.78% (P = 0.015 vs group B), 1.02% (P = 0.041 vs group B) and 1.12% (P = 0.093 vs group B), respectively. In contrast, indomethacin failed to induce apoptosis in gastric tumor (0.57% vs 0.50%, P = 0.54). Moreover, there was a significant difference in apoptotic indexes in the adjacent non-tumor tissues among different treatment groups (P = 0.003, ANOVA). The apoptotic index in non-tumor tissues increased from 0.13% in group B MNNNG to 0.43% in celecoxib 5 mg/(kg·d) (P = 0.009), 0.56% in celecoxib 10 mg/(kg·d) (P = 0.01), 0.48% in celecoxib 20 mg/(kg·d) groups (P = 0.001) and 0.42% in indomethacin group (P = 0.05), respectively.

**Statistical analysis**

Results were expressed as mean±SE. Comparisons among different treatment groups were made by (analysis of variance) ANOVA with Bonferroni’s multiple comparison tests. P<0.05 was considered statistically significant. All statistical calculations were carried out using the SPSS statistical software package (version 11.0, SPSS Inc.).
Effect of celecoxib or indomethacin on gastric epithelial cell proliferation

The highest proliferation index (22.1%) was seen in gastric tumors of MNNG-treated rats. Treatment with either celecoxib or indomethacin significantly reduced the tumor proliferation index ($P<0.001$, ANOVA; Figure 2B). The corresponding proliferation index in tumors treated with celecoxib 5, 10 and 20 mg/(kg·d) was 7.6% ($P<0.001$ vs group B), 2.9% ($P=0.012$ vs group B) and 4.6% ($P<0.001$ vs group B) respectively. Celecoxib at 5, 10 and 20 mg/(kg·d) inhibited tumor proliferation by 65.6%,

Figure 1 Histological examination of apoptosis and proliferation. Apoptosis was examined by apoptotic nuclei counting (A) and verified by TUNEL (B). A representative apoptotic nucleus is illustrated by the black arrow. Representative H&E stained sections showing apoptotic bodies (red arrow) in (C) MNNG-treated tumors, (D) celecoxib-treated tumors and (E) indomethacin-treated tumors. (F-H) Ki-67 immunostaining was used in the assessment of proliferation. Representative proliferating cells in (F) MNNG treated tumors, (G) celecoxib-treated tumors and (H) indomethacin-treated tumors indicated by positive immunoreactivity against Ki-67.

Figure 2 Effects of celecoxib/indomethacin treatment on gastric cell apoptosis and proliferation. A: Effects of celecoxib/indomethacin treatment on gastric cell apoptosis. The mean apoptotic index with standard error was shown. The apoptotic indexes were significantly higher in MNNG-induced tumor than in untreated control ($P = 0.001$). Moreover, the levels of apoptosis were significantly different among tumors (T), their adjacent non-tumor tissues (NT) and normal tissues from non-tumor rats (N) in all treatment groups ($^aP<0.005$ (T vs NT vs N), $^bP = 0.001$ (T vs N), $^cP<0.05$ (T, ANOVA), $^dP = 0.003$ (NT, ANOVA)). Treatment with celecoxib was associated with a higher apoptotic index in tumors ($P<0.05$, ANOVA) and their adjacent non-tumor tissues ($P = 0.003$, ANOVA). There appeared to be a dose-dependent increase in apoptotic index in celecoxib-treated tumors when compared to tumors treated with MNNG alone, but there was no significant increase in apoptotic index in indomethacin-treated tumors; B: The mean proliferation indexes with standard error. There were significant differences in the proliferation indexes among tumors ($P<0.001$, ANOVA) and their adjacent normal gastric tissues ($P = 0.01$, ANOVA). Specifically, tumors in MNNG group had the highest proliferation index than other treatment groups (group B vs all other groups, $P<0.003$).
86.9% and 79.2% respectively. Notably, the maximal anti-proliferative effect was achieved with celecoxib treatment at 10 mg/(kg·d). In contrast to apoptosis, similar anti-proliferative effects were noted in indomethacin-treated tumors (68.8% reduction, \( P = 0.001 \) vs group B).

In adjacent normal tissues, there was also a significant difference in the proliferation indexes among different treatment groups (\( P = 0.01 \), ANOVA). The highest proliferation index was found in the adjacent non-tumor tissues of group B MNNG treated rats (16.1%). The corresponding proliferation indexes in non-tumor tissues of rats treated with celecoxib 5 mg/(kg·d), 10 mg/(kg·d) and 20 mg/(kg·d) were 2.44% (or 85% reduction, \( P = 0.012 \) vs group B), 5.21% (or 67.6% reduction, \( P = 0.05 \) vs group B) and 3.63% (77.5% reduction, \( P = 0.05 \) vs group B). In contrast, there was no significant suppression of proliferation in non-tumor tissues of indomethacin group (10.7%, \( P = 0.05 \) vs group B). It was interesting to note that the proliferation of non-tumor gastric tissues appeared to be higher in indomethacin group than in those treated with celecoxib or MNNG control.

**Effects of celecoxib or indomethacin on ratio of apoptotic to proliferation index**

We also analyzed the ratio of apoptotic index to proliferation index (AI/PI) in gastric tumors of different treatment groups. As shown in Figure 3, there was a significant difference in the ratio among different treatment groups (\( P = 0.026 \), ANOVA). As shown in Table 1, the AI/PI ratio was found to be inversely proportional to the tumor incidences of different treatment groups. The lowest AI/PI ratio (0.03±0.012) was seen in group B MNNG-treated tumors which had the highest tumor incidence (75%). In contrast, the highest AI/PI ratio (0.51±0.34) was seen in rats treated with celecoxib at 10 mg/(kg·d) (Group D) with the lowest tumor incidence (18.8%).

![Figure 3](image_url)  
**Figure 3** Effects of celecoxib or indomethacin on the apoptosis index to proliferation ratio (AI/PI) in gastric tumors. The mean AI/PI ratio with standard error was shown. There was a significant difference in the AI/PI ratio among different treatment groups (\( P = 0.026 \), ANOVA). The highest ratio was seen in gastric tumors treated with celecoxib at 10 mg/(kg·d) whereas the lowest ratio was seen in tumors from MNNG group. The AI/PI ratio appeared to inversely correlate with the tumor incidence reported in different treatment groups (Table 1).

**DISCUSSION**

We have demonstrated in our recent study\(^{[20]}\) that treatment with celecoxib, but not indomethacin could significantly reduce the number of gastric tumor formations in rats and the maximal chemopreventive effect was seen in rats treated with a moderate dose of celecoxib 10 mg/(kg·d). Intriguingly, the lowest COX-2 and PGE\(_2\) levels were detected in indomethacin-treated tumors but not in celecoxib-treated groups, suggesting that the chemopreventive effect may not be mediated by COX-2 or PGE\(_2\) suppression alone. This study aimed to characterize the cell kinetic changes in stomachs of rats after treatment with celecoxib or indomethacin in order to gain more insights into the mechanisms underlying the chemopreventive effects of celecoxib. We found that treatment with celecoxib at all doses 5-20 mg/(kg·d) or indomethacin caused a marked inhibition of proliferation in gastric tumors and their adjacent normal tissues. On the other hand, it was noted that induction of apoptosis was only noticed in celecoxib-treated tumors but not in indomethacin-treated tumors. Together, celecoxib treatment resulted in both induction of apoptosis and inhibition of proliferation. In contrast, indomethacin was found to inhibit cell proliferation without induction of apoptosis in gastric tumors. These findings suggest that the mechanisms underlying the chemopreventive effect of celecoxib may be more related to its ability to induce apoptosis which was not found in indomethacin-treated group. More importantly, these findings help to explain the divergent chemopreventive responses of rat stomachs to these two agents which could not be explained by the level of COX-2 inhibition alone.

Although there was no induction of apoptosis by indomethacin in gastric tumors, we noticed that both indomethacin and celecoxib induced apoptosis in adjacent normal gastric tissues. The reason for this discrepant finding remains elusive but it is possible that neoplastic transformation of gastric epithelial cells may render them less susceptible to the pro-apoptotic effects of indomethacin. Intuitively, the use of a higher dose of indomethacin might be able to induce apoptosis in gastric tumor cells. The use of this dosage of 3 mg/(kg·d) is supported by previous animal chemopreventive studies\(^{[11,12]}\) and human daily recommendations. Moreover, results from our previous study\(^{[16]}\) provide unequivocal evidence that the current dosage is adequate in suppressing COX-2 and PGE\(_2\). Future studies may be necessary to characterize the effects of a high dose of indomethacin in gastric cancer chemoprevention. However, the use of a higher dosage may result in more gastrointestinal toxicity as reflected by the heightened proliferation in non-tumor tissues treated with the current dose of indomethacin (Figure 2B). This increase in gastric proliferation may be a compensatory response to the topical erosive effect of non-selective NSAIDs.

Moreover, the current study helps to explain the optimal dose of celecoxib used in chemoprevention of gastric cancer. As shown in Figure 3, treatment with celecoxib at 10 mg/(kg·d) was associated with the highest AI/PI ratio. Although we have shown in our previous study\(^{[16]}\) that the high dose celecoxib 20 mg/(kg·d) is associated with greater suppression of COX-2 activity and PGE\(_2\) level, this is not associated with a parallel rise in AI/PI ratio and higher chemopreventive effects. In line with our findings, Nishimura et al\(^{[20]}\) reported that induction of apoptosis was noted after treatment with a COX-2 inhibitor at a lower concentration than for the suppression of cell proliferation in a cancer xenograft model. It thus appears that the optimal dosage of celecoxib in chemoprevention is the dosage with the highest apoptosis to proliferation ratio.

Apart from suppression of prostaglandins, other possible pathways by which COX-2 inhibitors exert their pro-apoptotic effects have been previously addressed. It has been shown that NS398, a specific COX-2 inhibitor, could induce apoptosis in COX-2 expressing esophageal cancer cell line through the mitochondrial C-dependent pathway with activation of Caspase-9 and Caspase-3\(^{[21]}\). This is associated with minimal alterations in bcl-2, bax, c-myc, Fas and Fas-ligand expressions. A recent study also showed that celecoxib could induce apoptosis via a novel apoptosis-dependent but Bcl-2-independent mitochondrial pathway\(^{[22]}\). Both Fas-associated death domain protein and Bcl-2 are not involved in the induction of apoptosis by celecoxib in Jurkat T cells. This effect also appears to be independent of the ability to block COX-2. In addition, the failure of indomethacin to inhibit the development of MNNG-
induced gastric cancer may be explained by the inability of indomethacin to inhibit the activity of IκB kinase [23]. The NF-κB signaling pathway is another potential non-COX mediated-carcinogenesis pathway [24]. Activated NF-κB could translocate into the nuclei where it modulates the expression of a variety of genes, mostly through IκB kinase (IKK)-dependent phosphorylation and subsequent degradation of its inhibitors. It has been recognized that aspirin and sulindac, but not indomethacin, can inhibit the activity of IκB kinase β in vitro. Therefore, the failure of indomethacin to inhibit IκB kinase β may result in less COX-independent tumor suppression. Whether the difference in IκB kinase β inhibitory effects accounts for the differences in outcomes between indomethacin and celecoxib warrants further investigation.

In conclusion, these data help to explain the divergent chemopreventive effects of celecoxib and indomethacin in this animal model of gastric carcinogenesis. The chemopreventive effect of celecoxib is largely mediated by induction of apoptosis through a probable COX2-independent pathway. Further studies are necessary to characterize the pathways involved and the possible role of celecoxib in chemoprevention of human gastric cancer.

REFERENCES